52-Week Range
$215 – $305
Near 52-week high
Q1 2026 EPS
$5.07
+10% beat vs. $4.62E
FY2026E EPS
$21.50
Upward revision cycle
P/E (FY2026E)
14.2×
Sector: 12–13× avg.
ROTCE
~21%
Peers avg. 12–15%
CET1 Ratio
15.4%
~250bps above minimum
Dividend Yield
1.97%
+$1.40/qtr — 14 raises
Analyst Consensus
Buy
9B · 8H · 0S
12-Month Price History
Income Statement Forecast ($B) · E = Estimate
| FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|---|
| Revenue by Segment | ||||||
| Consumer & Community Banking (CCB) | $53.5B | $67.8B | $74.2B | $71.5B | $73.8B | $76.5B |
| Corporate & Investment Bank (CIB) | $50.2B | $54.9B | $61.7B | $65.0B | $70.5B | $75.0B |
| Asset & Wealth Mgmt. (AWM) | $16.3B | $18.9B | $20.8B | $22.5B | $24.2B | $26.0B |
| Corporate / Other | $7.7B | $16.7B | $20.3B | $14.0B | $14.5B | $15.0B |
| Total Net Revenue | $127.7B | $158.3B | $177.0B | $173.0B | $183.0B | $192.5B |
| YoY Growth | +7% | +24% | +12% | -2% | +6% | +5% |
| Profitability | ||||||
| Net Interest Income (NII) | $56.4B | $89.3B | $92.6B | $90.5B | $92.0B | $94.0B |
| Net Interest Margin (NIM) | 1.83% | 2.74% | 2.78% | 2.70% | 2.68% | 2.62% |
| Provision for Credit Losses | -$6.4B | -$9.3B | -$10.7B | -$11.5B | -$10.8B | -$10.5B |
| Noninterest Expense | -$76.1B | -$81.5B | -$90.0B | -$91.5B | -$94.0B | -$97.5B |
| Efficiency Ratio | 59.6% | 51.5% | 50.8% | 52.9% | 51.4% | 50.6% |
| Net Income | $37.7B | $49.6B | $58.5B | $54.0B | $58.0B | $61.5B |
| EPS (Diluted) | $12.09 | $16.23 | $21.09 | $20.40 | $21.50 | $23.25 |
| EPS Growth YoY | -22% | +34% | +30% | -3% | +5% | +8% |
| ROTCE | 17.6% | 21.0% | 22.4% | 19.8% | 21.2% | 22.0% |
Balance Sheet & Capital ($B) · E = Estimate
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Balance Sheet Highlights | |||||
| Total Assets | $3,875B | $4,000B | $4,150B | $4,280B | $4,420B |
| Total Deposits | $2,399B | $2,450B | $2,510B | $2,580B | $2,660B |
| Total Loans (Net) | $1,299B | $1,350B | $1,380B | $1,415B | $1,460B |
| Allowance for Loan Losses | $22.4B | $24.1B | $25.3B | $25.8B | $26.0B |
| Tangible Book Value / Share | $87.20 | $97.43 | $100.50 | $103.80 | $108.20 |
| Capital & Returns | |||||
| CET1 Ratio | 15.0% | 15.3% | 15.4% | 15.0% | 14.8% |
| Tier 1 Capital | $270B | $293B | $308B | $320B | $332B |
| Excess Capital (vs. min.) | ~$46B | ~$52B | ~$55B | ~$50B | ~$48B |
| Shareholder Returns | |||||
| Dividends Paid | -$12.8B | -$13.7B | -$14.9B | -$15.8B | -$16.8B |
| Share Buybacks | -$9.4B | -$23.8B | -$36.3B | -$25.0B | -$28.0B |
| Total Capital Returned | $22.2B | $37.5B | $51.2B | $40.8B | $44.8B |
Net Revenue & EPS Trajectory
Net Revenue ($B, left)
Diluted EPS (right)
Estimated
Valuation Framework
Base Case Price Target
$335
15.6× FY2026E EPS $21.50 · ~12% upside + 2% div
P/TBV & Excess Return Method
$320–$355
3.1–3.4× FY2026E TBV ~$103.80 · 21% ROTCE vs. 12% CoE
| Metric | JPM Current | JPM @ PT $335 | BAC | C | GS | WFC |
|---|---|---|---|---|---|---|
| JPMorgan Chase NYSE: JPM | $299.31 | $335 | — | — | — | — |
| Market Cap | ~$802B | ~$897B | ~$340B | ~$160B | ~$175B | ~$265B |
| P/E (FY2026E) | 14.2× | 15.6× | 12.0× | 9.8× | 14.0× | 12.5× |
| P/Tangible Book Value | 2.88× | 3.23× | 1.40× | 0.82× | 1.75× | 1.50× |
| ROTCE | ~21% | — | ~13% | ~11% | ~12% | ~14% |
| CET1 Ratio | 15.4% | — | 13.5% | 13.8% | 14.2% | 11.5% |
| Efficiency Ratio | 51.4%E | — | 66% | 64% | 67% | 63% |
| Dividend Yield | 1.97% | 1.76% | 2.7% | 3.1% | 2.5% | 2.9% |
| Consensus PT | $334.54 | $52 | $75 | $645 | $82 | |
JPM commands the highest P/TBV ratio among megabanks, reflecting its ~600–800bps ROTCE premium over peers. The P/TBV premium (2.9× vs. sector ~1.3×) is the market's acknowledgment that JPM generates ~$21 in earnings for every $100 of book value vs. ~$12 for BAC or ~$11 for Citigroup. At PT $335, P/E of 15.6× aligns with historical JPM peak multiples during prior periods of strong earnings visibility — a reasonable anchor given Q1 2026's 10% EPS beat and clear NII trajectory.
12-Month Price Target Scenarios
Bull Case
$400
+34% upside + dividend
Fed holds rates longer than expected, NII runs at $95B+ in FY2026. CIB achieves record fees on M&A rebound. Credit costs surprise positively — charge-off rate holds at 50bps. FY2026 EPS reaches $24.50. Multiple re-rates to 16.5× on ROTCE sustaining above 22%. Buybacks at maximum pace reduce share count faster.
Base Case
$335
+12% price + 2% div
NII holds near $92B on steady deposit base. CIB fee income in line with guidance. Credit quality stable — NCO rate in 55–60bps range. FY2026 EPS of $21.50. Multiple stays at 15.5×, supported by continued buyback activity. Dividend increased to $5.60/year in H2 2026 announcement.
Bear Case
$240
-20% downside
Rapid Fed rate cuts compress NII below $85B. Consumer credit deteriorates — charge-offs rise to 80–90bps, forcing $14B+ in provisions. CIB revenue drops on M&A slowdown. FY2026 EPS falls to $17.00. Regulatory capital surcharge raised, constraining buybacks. Multiple compresses to ~14× as ROTCE falls below 17%.
Key Catalysts — Next 12 Months
Jul 14, 2026
Q2 2026 Earnings — NII Trajectory & Credit Quality Update
Q2 results will be the most important near-term data point. Market is focused on (1) whether NII can sustain above $23B/quarter in a rate-cutting cycle, (2) whether net charge-offs are peaking, and (3) updated full-year fee guidance from CIB. A beat + maintained or raised FY2026E NII guide would likely push shares through $310+ and is our base case given the Q1 momentum.
H2 2026
Federal Reserve Rate Decision Cycle — NII Sensitivity
JPM has guided that each 25bps rate cut reduces NII by ~$500–$800M annualized. The Fed's projected 1–2 cuts in 2026 are manageable given deposit repricing dynamics and loan growth. However, an accelerated cut path (3+ cuts) due to deteriorating macro would compress NII more than modeled. Each quarter of rate stability adds ~$200M to consensus NII estimates.
Late 2026
Basel III Endgame — U.S. Capital Rule Finalization
The re-proposed U.S. Basel III Endgame rule is expected to be finalized in late 2026 with a reduced capital requirement increase vs. the original proposal. The revised rule is expected to require 9% more RWAs vs. the original 19% proposal. A favorable final rule would unlock additional excess capital for buybacks — JPM estimates each 1% CET1 reduction equals ~$15–17B available for return.
2026
CIB Rebound — M&A Advisory + Capital Markets Fees
Corporate M&A is recovering from a 2023–2024 trough — JPM CIB advisory revenue was up 10% in Q1 2026 and the pipeline is accelerating. A sustained rebound in CEO confidence and transaction activity would add $2–3B in incremental advisory fees. Equity issuance (IPOs, follow-ons) also recovering strongly, with Q1 2026 equity underwriting +43% YoY.
Ongoing
Wealth Management Scale & AWM Growth
JPM's Asset & Wealth Management segment has grown AUM to $3.9T+ with strong net inflows. At 26% margins and ~$24B revenue run rate in FY2026E, AWM is becoming a meaningful earnings diversifier against NII cyclicality. The segment's fee-based nature gives it a higher P/E multiple than the lending business, creating a sum-of-the-parts upside optionality.
Ongoing
Technology Investment Payoff — Deposit Retention + Cross-Sell
JPM's $17B+ annual technology spend — the largest of any bank globally — has created a digital banking moat: 88M active digital customers, 70M active mobile users, and industry-leading app ratings. This is translating into lower deposit runoff during rate cycles (+200bps deposit retention vs. peers in 2022–2023) and higher cross-sell ratios. Management has guided that tech spend will grow to $18.5B in 2027E.
Risk Register
High
NII Compression from Accelerated Fed Rate Cuts
JPM's NII of ~$90–92B/year is highly rate-sensitive. If the Fed cuts rates more aggressively than the current 1–2 cut consensus — driven by a recession scare or rapid disinflation — NII could compress to $82–85B and force a meaningful downward revision to FY2026E EPS. This is the single most important earnings driver to monitor. Every unexpected 25bps cut reduces our NII estimate by $600–800M.
High
Consumer Credit Cycle Deterioration
JPM's consumer portfolio ($680B+) is showing early signs of normalization — net charge-offs rose to 56bps in Q1 2026 from 35bps in Q1 2024. If unemployment rises materially (above 5.5%), charge-offs could spike to 80–100bps, requiring an additional $4–6B in provision build. Credit card delinquencies (30+ days) are the leading indicator to watch — currently at 2.1%, up from 1.3% in 2022.
Med
Basel III Endgame Capital Increase
Even the revised, reduced Basel III Endgame proposal adds ~9% to JPM's RWA, requiring ~$12–15B in additional capital. This effectively freezes that capital — reducing buyback capacity by an estimated $5–8B over the 2026–2028 transition period. A surprising reversal back to the original proposal (19% RWA increase) would reduce buybacks by $30B+ and compress EPS growth estimates materially.
Med
CEO Succession & Strategic Continuity
Jamie Dimon has indicated he plans to remain CEO for "another 3–5 years," but any surprise departure would create uncertainty. JPM trades at a meaningful "Dimon premium" — analysts estimate 10–15% of its current P/E premium is attributable to his leadership track record. While a succession plan exists, any unplanned transition would likely compress the multiple toward sector averages at 12–13×.
Med
Commercial Real Estate Exposure
JPM has ~$68B in office CRE exposure. While JPM is better reserved than regional banks, continued office vacancy pressure (national vacancy rate ~20%+) could require incremental provisioning of $1–2B in FY2026–2027. Management has guided to manageable losses, but the portfolio is in a work-out phase that could extend 2–3 years beyond current expectations.
Low
Regulatory / Political Headwinds
Political pressure on bank fees (overdraft, interchange) has been an ongoing headwind — CFPB overdraft rule impact was ~$500M/year for JPM in prior years. The deregulatory stance of the current administration has reduced this risk materially. Any reinstatement of aggressive consumer finance regulation would modestly impact noninterest income but is unlikely to be a material earnings driver at JPM's scale.
Market Sentiment & Positioning
Analyst Rating
Buy
9 Buy · 8 Hold · 0 Sell
Avg Price Target
$334.54
Range: $285 – $395
Hedge Fund Flow
Positive
Top 10 position for 32 HFs
Insider Activity
Selling
Dimon executed planned sales
Short Interest
0.9%
Very low — minimal bearish bets
SmartScore
6/10
Neutral — insider drag
Options Sentiment
Bullish
Call / Put ratio 1.8×
Institutional Ownership
74.2%
Vanguard 9.1%, BLK 7.4%
The Bottom Line
▶ Investment Conclusion · BUY · PT $335
JPMorgan Chase is in one of the best positions in its history. A decade of technology investment has produced structural advantages in deposit retention, cross-sell economics, and client capture that are only widening relative to the regional banking sector — which continues to face deposit fragility, capital constraints, and technology underinvestment. Meanwhile, JPM's balance sheet has never been stronger: $55B+ in excess capital, 15.4% CET1, and $40–51B in annual capital return capacity.
The Q1 2026 results — EPS $5.07 (+10% beat), NII $23.4B, ROTCE 21% — confirmed that the bull case thesis is tracking ahead of schedule. Credit quality, while normalizing, remains well within manageable bounds, and the CIB fee pipeline is accelerating alongside a recovering M&A market. The bear case risk of rapid Fed cuts and associated NII compression is real but is already partially discounted in the stock at 14× forward earnings — below JPM's own 5-year average P/E of 14.5× despite a stronger franchise today.
At PT $335 (15.6× FY2026E EPS), we are not asking for a multiple expansion — we are simply asking for the stock to reflect current earnings power. With $21.50 in 2026E EPS, $23.25E in 2027E, and a dividend growing at ~6% annually, JPM is a core financial holding. We rate JPM BUY.
The Q1 2026 results — EPS $5.07 (+10% beat), NII $23.4B, ROTCE 21% — confirmed that the bull case thesis is tracking ahead of schedule. Credit quality, while normalizing, remains well within manageable bounds, and the CIB fee pipeline is accelerating alongside a recovering M&A market. The bear case risk of rapid Fed cuts and associated NII compression is real but is already partially discounted in the stock at 14× forward earnings — below JPM's own 5-year average P/E of 14.5× despite a stronger franchise today.
At PT $335 (15.6× FY2026E EPS), we are not asking for a multiple expansion — we are simply asking for the stock to reflect current earnings power. With $21.50 in 2026E EPS, $23.25E in 2027E, and a dividend growing at ~6% annually, JPM is a core financial holding. We rate JPM BUY.
MARKET BUZZ RESEARCH — This report is for informational purposes only and does not constitute financial advice. All estimates are Market Buzz projections. Past performance is not indicative of future results. See full disclosures at MarketBuzz.com/disclosures. Data as of June 1, 2026.